Multicentric randomized non-comparative, open-label, phase II trial, based on signle-stage design, to assess the preliminary signs of antitumor activity of darolutamide plus radiation therapy in patients with unfavorable intermediate risk prostate cancer.~Patients satisfying eligibility criteria will be randomized according to 2 treatment modalities~Arm A (experimental arm): combination of external beam radiotherapy (EBRT) and 6 months darolutamide.~Arm B (standard arm): combination of external beam radiotherapy (EBRT) and 6 months ADT (androgen deprivation therapy)~Two patients randomized in arm A for one patient randomized in arm B.
Randomized non-comparative phase II trial to assess the preliminary signs of antitumor activity of darolutamide plus radiation therapy in patients with unfavorable intermediate risk prostate cancer.